Harwin Peter Evan 4
4 · Viridian Therapeutics, Inc.\DE · Filed Jun 10, 2022
Insider Transaction Report
Form 4
Harwin Peter Evan
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-06-08+12,500→ 12,500 total(indirect: See footnote)Exercise: $12.31Exp: 2032-06-08→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]The option vests in full upon the earlier to occur of (i) June 8, 2023 or (ii) the Issuer's 2023 annual meeting of stockholders, subject to Reporting Person's continued service on the Board.
- [F2]Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.